Evidence map›Paper›PMID 29520477›Full record

ArticlePharmaceutical research2018

Biodistribution and Pharmacokinetic Evaluations of a Novel Taxoid DHA-SBT-1214 in an Oil-in-Water Nanoemulsion Formulation in Naïve and Tumor-Bearing Mice.

Gulzar Ahmad, Florence Gattacecca, Rana El Sadda, Galina Botchkina, Iwao Ojima, James Egan, Mansoor Amiji

Abstract read
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gulzar AhmadDepartment of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, 02115-5000, USA.
Florence GattaceccaInstitut de Recherche en Cancérologie de Montpellier IRCM, INSERM U1194, ICM, Université de Montpellier, Montpellier, France.
Rana El SaddaInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, 11794-3400, USA.
Galina BotchkinaInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, 11794-3400, USA.
Iwao OjimaInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, 11794-3400, USA.
James EganTargagenix, Inc., 25 Health Sciences Drive, Stony Brook, New York, 11790-3382, USA.
Mansoor AmijiDepartment of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, 02115-5000, USA. m.amiji@northeastern.edu.

Funding

Tumor -Targeting Chemotherapeutic AgentsR01CA103314 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI OJIMA, IWAO · 2003 to 2013
$3.1M
Preclinical Studies on Polyunsaturated Fatty Acid-Taxoid Conjugate for IND FilingR44CA132396 · NCI · CHEM-MASTER INTERNATIONAL, INC · PI GUPTA, RAMESH CHANDER · 2010 to 2011
$2.7M
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCEU01CA151452 · NCI · NORTHEASTERN UNIVERSITY · PI AMIJI, MANSOOR M., DUAN, ZHENFENG · 2010 to 2014
$2.1M
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-VectorsR21CA213114 · NCI · NORTHEASTERN UNIVERSITY · PI AMIJI, MANSOOR M., MACKENZIE, GERARDO GUILLERMO · 2017 to 2018
$388k
Targeted Platinates/siRNA Combination Therapy for Resistant Lung CancerR21CA179652 · NCI · NORTHEASTERN UNIVERSITY · PI AMIJI, MANSOOR M., IYER, ARUN · 2014 to 2015
$372k
PROSTATE CANCER STEM CELL-TARGETED ACTIVITY OF A NEW-GENERATION TAXOIDSR21CA150085 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI BOTCHKINA, GALINA I · 2010 to 2011
$371k
Peclinical Studies on a Polyunsaturated Fatty acid-Taxoid Conjugate for IND FiliR43CA132396 · NCI · CHEM-MASTER INTERNATIONAL, INC · PI GUPTA, RAMESH CHANDER · 2008 to 2008
$99k
NCI NIH HHS CA103314NCI NIH HHS CA132396NCI NIH HHS CA150085NCI NIH HHS CA151452NCI NIH HHS CA179652NCI NIH HHS HHSN261201500018CNCI NIH HHS R01 CA103314NCI NIH HHS R21 CA150085NCI NIH HHS R21 CA179652NCI NIH HHS R21 CA213114NCI NIH HHS R44 CA132396NCI NIH HHS U01 CA151452
6 · The paper itself

Abstract

purposeThe main purpose of this study was to formulate an oil-in-water nanoemulsion of a next generation taxoid DHA-SBT-1214 and evaluate its biodistribution and pharmacokinetics.

methodsDHA-SBT-1214 was encapsulated in a fish oil containing nanoemulsion using a high pressure homogenization method. Following morphological characterization of the nanoemulsions, qualitative and quantitative biodistribution was evaluated in naïve and cancer stem cell-enriched PPT-2 human prostate tumor bearing mice.

resultsDHA-SBT-1214 was successfully encapsulated up to 20 mg/ml in the nanoemulsion formulation and had an average oil droplet size of 200 nm. Using a DiR near infra-red dye encapsulated nanoemulsion, we have shown the delivery of nanoemulsion to mouse tumor region. By quantitative analysis, DHA-SBT-1214 encapsulated nanoemulsion demonstrated improved pharmacokinetic properties in plasma and different tissues as compared to its solution form. Furthermore, the nanoemulsions were stable and had slower in vitro drug release compared to its solution form.

conclusionsThe results from this study demonstrated effective encapsulation of the drug in a nanoemulsion and this nanoemulsion showed sustained plasma levels and enhanced tumor delivery relative to the solution form.

Indexed as

Administration, IntravenousAnimalsAntineoplastic AgentsCell Line, TumorDocosahexaenoic AcidsDrug CompoundingDrug LiberationEmulsionsHumansMaleMiceMice, Inbred NODMice, SCIDNanoparticlesNeoplasmsTaxoidsAntineoplastic AgentsDocosahexaenoic AcidsEmulsionsSB T-1214Taxoidsbiodistribution and pharmacokineticnanoemulsion formulationprostate tumortaxoid

Identifiers

PMID29520477
PMCPMC6151135

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.